coronavirus covid-19 sars-cov-2 illustration

CORONAVIRUS RESEARCH

Georgia State scientists are unraveling how the coronavirus operates, searching for effective treatments and diving into the pandemic’s impact on the economy and society. Learn more below about how our research community is making a difference.

ADDITIONAL RESOURCES

CORONAVIRUS EXPERTS GUIDE CORONAVIRUS NEWS HUB

Research Science Center building on Georgia State University's campus

BRINGING FORWARD A NEW ANTIVIRAL TREATMENT

Georgia State scientists were the first to demonstrate that molnupiravir was orally active against SARS-CoV-2. The antiviral drug has been recommended for emergency use authorization to treat COVID-19.

INCREASING VACCINE UPTAKE

With a grant from the CDC, Georgia State’s Prevention Research Center is working to increase COVID-19 vaccination rates among refugees and other groups in Clarkston — one of the largest refugee resettlement communities in the U.S.

LEARN MORE

USING SOCIAL MEDIA TO MAP DISEASE

Juan Banda, assistant professor in the Department of Computer Science, is tapping into Twitter data to learn more about people’s experiences during the pandemic.

LEARN MORE

PROTECTING THE VULNERABLE

Georgia State researchers are teaming up with their colleagues at Emory School of Medicine to help nursing homes mitigate the impact of COVID-19 and stop the spread of SARS-CoV-2.

Variant Type and Patient Sex Affect Molnupiravir Efficacy, Study Finds

Published August 1, 2022 in Georgia State News Hub

SARS-CoV-2 variants of concern and the biological sex of patients affect the efficacy of molnupiravir, the first orally available drug approved for outpatient use against COVID-19, according to a new study led by researchers at Georgia State University.

Corona Virus B.1.1.529 Mutation Illustration with blue background

Georgia State Study Finds COVID-19 Omicron Variant Leads to Less Severe Disease in Mice

Published June 27, 2022 in Georgia State News Hub

Mukesh Kumar and his team of biology researchers found mice were more likely to get infected by Omicron than other variants but with significantly lower mortality rates.

MORE CORONAVIRUS RESEARCH NEWS

Team Up With Our Researchers

Interested in collaborating with Georgia State scientists on coronavirus research? Contact our Office of Technology Transfer and Commercialization.

Subscribe To Our Newsletter

Subscribe to our research magazine and monthly e-newsletter and see how we’re making discoveries #THESTATEWAY^®

Contact Us

Timothy L. Denning
Vice President for Research and Economic Development
tdenning@gsu.edu

Noelle Toumey Reetz
Communications Manager
ntoumey1@gsu.edu

Research Administration
404-413-3500
research@gsu.edu

University Research